missed Wall Street's fourth-quarter estimates by a penny, as sales fell 11% from the year-ago period, in part because of the strong dollar overseas.
For the fourth quarter ended Dec. 31, earnings fell to $87 million, or 22 cents a share, from $107 million, or 26 cents a share, in the same period last year.
First Call/Thomson Financial
polled 22 analysts, who arrived at a consensus estimate of 23 cents a share.
The medical device maker reported fourth-quarter revenue of $638 million, down from $717 million a year ago. Disappointing sales of coronary stents and balloons contributed to the decline.
Shares of Boston Scientific, which is based in Natick, Mass., ended
New York Stock Exchange
trading at $16.12, up 9 cents, or 0.6% on the day.